Objective
Comprehensive assessment of dissolvable microneedle technology (dMTS) and identification of top licensing partner companies through an extensive secondary and&nbsp;<a href="https://www.delveinsight.com/consulting/primary-research-services">primary research</a>&nbsp;study.
Problem Statement
A&nbsp;leading U.S.-based company&nbsp;specializing in&nbsp;<a href="https://www.delveinsight.com/report-store/drug-delivery-devices-market">drug delivery devices</a>&nbsp;with a strong global commercialization presence sought to&nbsp;<a href="https://www.delveinsight.com/consulting/licensing-services">in-license</a>&nbsp;a potential dissolvable microneedle technology system (dMTS). The goal was to identify companies actively engaged in&nbsp;microneedle research and innovation&nbsp;and evaluate their capabilities in&nbsp;developing, manufacturing, and commercializing drug delivery solutions.
The client aimed to&nbsp;expand their portfolio with a&nbsp;non-invasive and&nbsp;<a href="https://www.delveinsight.com/report-store/novel-drug-delivery-devices">novel drug delivery</a>&nbsp;method, leveraging&nbsp;microneedle patches&nbsp;for effective therapeutic delivery of various drugs and vaccines. This approach aligned with the growing market demand for&nbsp;pain-free, patient-friendly, and self-administrable&nbsp;drug delivery systems.
To ensure a&nbsp;strategic and well-informed licensing decision, the client required:
<ul style="text-align: left;" type="disc">
<li>A&nbsp;detailed assessment of the dMTS market, including current innovations, adoption trends, and competitive landscape.</li>
<li>Identification of top companies&nbsp;with cutting-edge microneedle technology that aligned with their commercialization objectives.</li>
<li>Evaluation of technological competencies, including formulation techniques, patch design, scalability, and regulatory compliance.</li>
<li>Clinical capabilities assessment, focusing on companies with established preclinical and clinical-stage products.</li>
<li>Commercial readiness analysis, ensuring that shortlisted companies possessed the necessary infrastructure for successful product launch and large-scale production.</li>
</ul>
Recognizing the complexity of this rapidly evolving market, the client collaborated with&nbsp;DelveInsight&nbsp;to conduct a&nbsp;comprehensive industry analysis&nbsp;and facilitate potential licensing discussions.
Our Approach &amp; Methodology
To meet the client&rsquo;s strategic objectives, we adopted a&nbsp;multi-dimensional assessment framework&nbsp;that integrated market research, competitive intelligence, and direct stakeholder engagement.
1. dMTS Market Assessment
<ul style="text-align: left;" type="disc">
<li>Conducted an&nbsp;in-depth evaluation of the global dissolvable microneedle technology market, highlighting:</li>
<ul type="circle">
<li>Current and&nbsp;emerging trends&nbsp;in dMTS adoption.</li>
<li>The&nbsp;regulatory landscape&nbsp;governing microneedle-based drug delivery.</li>
<li>The&nbsp;market size, growth trajectory, and forecast&nbsp;for dMTS applications.</li>
</ul>
</ul>
2. Companies Assessment
<ul style="text-align: left;" type="disc">
<li>Identified a&nbsp;broad pool of companies&nbsp;engaged in dMTS research and development.</li>
<li>Analyzed their&nbsp;market positioning, technological capabilities, and commercial strengths.</li>
<li>Prioritized companies with a&nbsp;strong research pipeline and proven clinical feasibility.</li>
</ul>
3. Technology Assessment
<ul style="text-align: left;" type="disc">
<li>Examined the&nbsp;core technology platforms&nbsp;employed by various companies, assessing:</li>
<ul type="circle">
<li>Formulation approaches&nbsp;for drug incorporation in dissolvable microneedles.</li>
<li>Fabrication techniques&nbsp;ensuring precision, stability, and efficacy.</li>
<li>Delivery mechanisms&nbsp;and their compatibility with different drug classes.</li>
<li>IP landscape, including patents and proprietary innovations.</li>
</ul>
</ul>
4. Investment Assessment
<ul style="text-align: left;" type="disc">
<li>Evaluated the&nbsp;funding and investment status&nbsp;of identified companies, including:</li>
<ul type="circle">
<li>Venture capital involvement.</li>
<li>Research grants and government funding.</li>
<li>Financial stability and potential for strategic partnerships.</li>
</ul>
</ul>
5. Primary Intelligence Gathering
<ul style="text-align: left;" type="disc">
<li>Conducted&nbsp;direct interactions with industry experts, including:</li>
<ul type="circle">
<li>Executives from leading dMTS companies.</li>
<li>Key opinion leaders (KOLs) in drug delivery technology.</li>
<li>Regulatory consultants with expertise in microneedle-based products.</li>
</ul>
<li>Gathered insights on&nbsp;R&amp;D pipelines, clinical trial progress, and potential licensing opportunities.</li>
</ul>
6. Strategic Insights on Companies
<ul style="text-align: left;" type="disc">
<li>Performed&nbsp;SWOT analyses&nbsp;of shortlisted companies to determine their:</li>
<ul type="circle">
<li>Strengths&nbsp;in technology and product development.</li>
<li>Weaknesses, such as regulatory hurdles or scalability challenges.</li>
<li>Opportunities&nbsp;for collaboration and licensing.</li>
<li>Threats, including competitive risks and market saturation.</li>
</ul>
</ul>
7. Assessment of the Client&rsquo;s Own Positioning
<ul style="text-align: left;" type="disc">
<li>Conducted an&nbsp;internal evaluation&nbsp;of the client&rsquo;s capabilities to integrate dMTS technology.</li>
<li>Assessed their&nbsp;manufacturing, commercialization, and regulatory readiness.</li>
<li>Identified potential&nbsp;synergies between the client&rsquo;s existing portfolio and dMTS technology.</li>
</ul>
8. Strategic Goal Building
<ul style="text-align: left;" type="disc">
<li>Defined a&nbsp;targeted licensing strategy&nbsp;based on market insights.</li>
<li>Developed a&nbsp;roadmap for partnership formation, including timelines and key action points.</li>
<li>Recommended approaches for&nbsp;contract negotiations and due diligence.</li>
</ul>
Results &amp; Key Insights
Our rigorous assessment provided the client with:
1. Matrix Analysis of the Top 20 Companies
<ul style="text-align: left;" type="disc">
<li>A&nbsp;comprehensive competitive intelligence matrix&nbsp;positioning the&nbsp;top 20 companies&nbsp;in the dissolvable microneedle space.</li>
<li>Categorization of companies based on&nbsp;technology readiness, clinical progress, and commercialization potential.</li>
<li>A&nbsp;targeted quadrant analysis&nbsp;highlighting companies best suited for licensing partnerships.</li>
</ul>
2. Identification of the Top Licensing Candidates
<ul style="text-align: left;" type="disc">
<li>The client could efficiently&nbsp;assess and shortlist&nbsp;the companies that aligned with their strategic objectives.</li>
<li>The&nbsp;top-tier candidates (TARGET quadrant)&nbsp;were identified based on:</li>
<ul type="circle">
<li>Innovative microneedle patch technologies.</li>
<li>Proven clinical efficacy&nbsp;and regulatory feasibility.</li>
<li>Scalability for mass production and commercial deployment.</li>
</ul>
</ul>
3. Direct Industry Engagement &amp; Partnership Facilitation
<ul style="text-align: left;" type="disc">
<li>DelveInsight arranged exclusive meetings&nbsp;with&nbsp;4-5 top companies, enabling the client to initiate&nbsp;direct discussions&nbsp;on licensing and collaboration.</li>
<li>Provided&nbsp;key negotiation insights, helping the client establish&nbsp;strong strategic partnerships.</li>
</ul>
4. Clear Roadmap for Licensing &amp; Product Integration
<ul style="text-align: left;" type="disc">
<li>Delivered a&nbsp;customized licensing roadmap, outlining:</li>
<ul type="circle">
<li>The&nbsp;ideal partnership model&nbsp;(co-development, in-licensing, joint ventures).</li>
<li>Regulatory considerations&nbsp;for dMTS adoption.</li>
<li>Operational and manufacturing integration strategies&nbsp;for seamless product launch.</li>
</ul>
</ul>
Conclusion
Through&nbsp;comprehensive market intelligence and strategic insights, the client successfully identified and engaged with&nbsp;top-tier microneedle technology companies, bringing them closer to securing a&nbsp;high-value licensing agreement.
By leveraging&nbsp;DelveInsight&rsquo;s expertise, the client:
<ul style="text-align: left;" type="disc">
<li>Minimized the risk&nbsp;of investing in underdeveloped technologies.</li>
<li>Optimized their licensing strategy, ensuring alignment with long-term commercialization goals.</li>
<li>Streamlined decision-making, accelerating their entry into the dissolvable microneedle-based drug delivery market.</li>
</ul>
This study not only enabled the client to strategically position themselves in the competitive dMTS landscape but also set the foundation for future expansion into non-invasive drug delivery innovations.

A large client based in USA, involved in drug delivery devices, with effective marketing and commercialization presence across the globe, wanted to in-license potential dMTS based drug delivery asset from companies involved in microneedle technology research for delivering therapeutic products.  

In-Licensing Opportunity

Review case study how a Europe based client involved DelveInsight for in-licensing product from a partner.